基因疫苗诱导小鼠抗HBV皮下移植瘤免疫研究

目的　观察 ＨＢＶ ＤＮＡ 疫苗（ｐＣＲ３－１Ｓ） 诱导Ｂａｌｂ／ ｃ 小鼠（ Ｈ２ｄ） 的特异性细胞免疫应答及其对稳定表达ＨＢｓＡｇ 的小鼠肥大细胞瘤Ｐ８１５ 细胞（Ｐ８１５ＨＢＶＳ） （ Ｈ２ｄ） 成瘤性的影响．方法　肌肉注射ＤＮＡ 疫苗，背部皮下接种Ｐ８１５ＨＢＶＳ 细胞，观察成瘤情况，４ ｈ ５１Ｃｒ 释放法检测小鼠脾细胞ＣＴＬ 活性．结果　接种 ＤＮＡ 疫苗后小鼠成瘤率为１２－５ ％ ， 对照组为１００ ％ ． 小鼠平均存活期大于３８－２ ｄ ，对照组为２８－４ ｄ ，４０ ｄ 后小鼠存活率为８７－５ ％ ，对照组为０ ％ ． ＣＴＬ 细胞杀伤活性明显增加，ｐＣＲ３－１Ｓ 组５１ ％ ，对照组为２１ ％ （ Ｐ＜ ０－００１） ．结论　ＤＮＡ 疫苗可以诱导细胞免疫应答，对体内ＨＢＶ 感染具有预防及治疗作用．

Study on immunization ofanti subcutaneous transplanting tumor induced by gene vaccine

AIM To observe the specific cellular immune responses and the protection against P815 mastocytoma cells stable expressing HBV surface antigen (P815 HBV S) in Balb/*!c (H 2 d) mice after DNA immunization of HBV surface antigen (pCR3 1 S). METHODS The immunization was performed by intramuscular injection in this experiment. Three weeks later, we directly inoculated P815 HBV S into mice by subcutaneous injection. The tumor growth was measured every five days and HBsAg specific cytotoxic T lymphocytes (CTLs) activity was measured by 51 Chromiun release assay. RESULTS HBV S DNA vaccine can evidently inhibit the tumor growth, prolong the survival period (>38 2*!d) and improve the survival rate (87 5%) in mice. Meanwhile, HBsAg specific CTLs activity were obviously increased after DNA immunization (51% vs 21%, P <0 001 ). CONCLUSION The results showed that the DNA vaccine of pCR3 1 S had strong antigenecity in cellular immunity and had marked killing effect on HBV infected cells in vivo . DNA vaccine against HBV may be useful for both prophylactic and therapeutic purposes.